Active Not RecruitingNCT05625555
Predictors of response to intravenous ketamine for difficult-to-treat depression
About this title
Read the official source — NCT05625555Medication studyAges 18–65Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- HalifaxSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 19, 2024
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Abraham Nunes
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05625555
- Official title
Show the full official title
Clinical Predictors of Intravenous Ketamine Response in Treatment-Resistant Depression: A Randomized, Double-Blind, Midazolam-Controlled Pilot Study
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Halifax
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Abraham Nunes.
Does this study involve medication?
Yes. The study involves medication, including ketamine and Midazolam.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
